A Phase 1/2 interventional study of TLC590 and Naropin in Inguinal Hernia, sponsored by Taiwan Liposome Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-14.
Sponsored by Taiwan Liposome Company · Phase 1/2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Hernia, Inguinal with a site in United States — 9 open to participants now, 20 under way, none of them phase 3. Hernia, Inguinal · United States.
Among the 77 studies in Hernia, Inguinal with a site in United States, this one is the 37th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2018, is the only one in phase 1/2, and was the 43rd registered.
545 studies on the registry are indexed under Hernia, Inguinal; 93 are open to participants now.
Browse Hernia, Inguinal studies →9 of the 77 studies in Hernia, Inguinal with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 50+ · Men only
Northwestern University · Sites in United States
Ages 18+
Distalmotion SA · Sites in United States
Ages 22+
University of Michigan · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Hernia, Inguinal studies recruiting now, 30 (54%) set no upper age limit and 17 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 7 · Phase 4 10
First in 1987; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 90 across 397 interventional studies indexed under Hernia, Inguinal.
Median enrollment 100 across the 60 interventional studies, 116 across the 17 observational. Of the 50 that completed or were terminated, 24 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 77 have an industry lead sponsor. The 10 most frequent:
Taiwan Liposome Company is the lead sponsor of 18 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Taiwan Liposome Company has 1 study filed under Hernia, Inguinal — fewer than ten, so there is no comparison to draw.
4 of the studies in Hernia, Inguinal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06934564University of MichiganDe-Implementation of Low-value Testing in Patients Undergoing Low-Risk Surgery | 2026-12 |
| NCT04779918Tela Bio IncVentral or Inguinal Hernia, Robotically Repaired With OviTex Mesh | 2027-03-30 |
| NCT05388929Prisma Health-UpstateMethocarbamol in Ventral and Inguinal HR | 2027-06 |
| NCT05929937Clayton PetroNo Opioids vs. Minimal Opioids Following Inguinal Hernia Repair | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 77 studies in Hernia, Inguinal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study to assess the safety, PK, and efficacy of single postsurgical application of TLC590 compared with Naropin®
A Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study to assess the safety, PK, and efficacy of single postsurgical application of TLC590 compared with Naropin® via a single infiltrative local administration in adult subjects following inguinal hernia repair surgery.
Approximately 64 evaluable subjects across 4 cohorts. Dose escalation of a single postsurgical administration of TLC590 or Naropin® will be performed. Dose escalation will be determined by review of treatment-related adverse events and all serious adverse events (AEs) by a safety monitoring committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of any of the following medications within 5 half-lives or as specified prior to the study surgical procedure:
Anti- agents such as aspirin therapy within 7 days; clopidogrel within 5 days; Anticoagulants such as warfarin within 5 days; dabigatran etexilate mesylate within 2 days; factor Xa inhibitor within 24 hours; Class III antiarrhythmic drugs (e.g., amiodarone); Strong CYP1A2 inhibitors, such as cimetidine, ciprofloxacin, enoxacin, and fluvoxamine; CYP1A2 substrates, such as theophylline or imipramine; Strong inhibitors such as voriconazole, erythromycin, ketoconazole, or ritonavir; CYP3A4 substrates, such as atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, or tipranavir; , either systemically, inhaled, intranasally, orally, or by intra-articular injection within 14 days before the study surgical procedure (topical corticosteroid is allowed); Non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to the study surgical procedure; Any product within 30 days prior to administration of blinded study medication.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
Drug: TLC590
TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
Drug: TLC590
TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
Drug: TLC590
TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
Drug: TLC590
Naropin injection contains ropivacaine hydrochloride (HCl). Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
Drug: Naropin
TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
Also known as: TLC590 (Ropivacaine Liposome Injectable Suspension)
Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
Also known as: Naropin, 0.5% Injectable Solution
Safety and Tolerability: Event of SAE and Treatment-related Severe AE
Event of serious adverse event (SAE) and treatment-related severe adverse event (TRAE)
Time frame: Screening till 30 days post investigational product (IP) administration, up to 58 days
| Milestone | TLC590 190mg | TLC590 380mg | TLC590 570mg | TLC590 475mg | Naropin 150mg |
|---|---|---|---|---|---|
| Started | 12 | 0 | 0 | 0 | 4 |
| Completed | 12 | 0 | 0 | 0 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Milestone | TLC590 190mg | TLC590 380mg | TLC590 570mg | TLC590 475mg | Naropin 150mg |
|---|---|---|---|---|---|
| Started | 0 | 12 | 0 | 0 | 5 |
| Completed | 0 | 11 | 0 | 0 | 4 |
| Not completed | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
| Milestone | TLC590 190mg | TLC590 380mg | TLC590 570mg | TLC590 475mg | Naropin 150mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 12 | 0 | 4 |
| Completed | 0 | 0 | 11 | 0 | 3 |
| Not completed | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 1 |
| Milestone | TLC590 190mg | TLC590 380mg | TLC590 570mg | TLC590 475mg | Naropin 150mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 12 | 4 |
| Completed | 0 | 0 | 0 | 12 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Event of serious adverse event (SAE) and treatment-related severe adverse event (TRAE)
| Event | TLC590 190mg | TLC590 380mg | TLC570mg | TLC590 475mg | Naropin |
|---|---|---|---|---|---|
| Safety and Tolerability: Event of SAE and Treatment-related Severe AE | 2 | 1 | 2 | 2 | 2 |
Collected over 58 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TLC590 190mg | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| TLC590 380mg | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| TL590 570mg | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| TLC590 475mg | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Naropin 150mg | 0/16 (0%) | 0/16 (0%) | 13/16 (81.3%) |
| Event | TLC590 190mg | TLC590 380mg | TL590 570mg | TLC590 475mg | Naropin 150mg |
|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 2/12 | 1/12 | 3/12 | 1/12 | 8/16 |
| NauseaGastrointestinal disorders | 4/12 | 2/12 | 2/12 | 5/12 | 7/16 |
| HeadacheNervous system disorders | 2/12 | 0/12 | 1/12 | 4/12 | 3/16 |
| PyrexiaGeneral disorders | 4/12 | 2/12 | 0/12 | 2/12 | 0/16 |
| VomitingGastrointestinal disorders | 2/12 | 2/12 | 0/12 | 2/12 | 5/16 |
| ParaesthesiaNervous system disorders | 0/12 | 0/12 | 3/12 | 0/12 | 0/16 |
| DizzinessNervous system disorders | 2/12 | 2/12 | 0/12 | 2/12 | 1/16 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 2/12 | 0/12 | 0/12 | 0/12 | 0/16 |
| FallInjury, poisoning and procedural complications | 0/12 | 0/12 | 2/12 | 0/12 | 0/16 |
| Back painMusculoskeletal and connective tissue disorders | 0/12 | 1/12 | 0/12 | 2/12 | 0/16 |
One subject who was randomized (period 2, Naropin group) did not receive any treatment (withdraw by subject), and was replaced. This subject was not included in any analysis population.
| Age, Categorical(Participants) | TLC590 190mg | TLC590 380mg | TLC590 570mg | TLC590 475mg | Naropin 150mg | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 12 | 12 | 12 | 16 | 64 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | TLC590 190mg | TLC590 380mg | TLC590 570mg | TLC590 475mg | Naropin 150mg | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 1 | 0 | 2 | 1 | 4 |
| Male | 12 | 11 | 12 | 10 | 15 | 60 |
| Ethnicity (NIH/OMB)(Participants) | TLC590 190mg | TLC590 380mg | TLC590 570mg | TLC590 475mg | Naropin 150mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 12 | 12 | 12 | 16 | 63 |
| Not Hispanic or Latino | 1 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | TLC590 190mg | TLC590 380mg | TLC590 570mg | TLC590 475mg | Naropin 150mg | Total |
|---|---|---|---|---|---|---|
| United States | 12 | 12 | 12 | 12 | 16 | 64 |
| Body Mass Index (BMI)(Participants) | TLC590 190mg | TLC590 380mg | TLC590 570mg | TLC590 475mg | Naropin 150mg | Total |
|---|---|---|---|---|---|---|
| BMI <=35 kg/m2 | 12 | 12 | 12 | 12 | 16 | 64 |
| BMI > 35 kg/m2 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Jan 2019, 5 months.
Results were first posted in Jul 2021, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
Taiwan Liposome Company